An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

A widely used supplement for joint health has been linked to a faster Alzheimer's progression, raising questions about whether glucosamine could turn mild cognitive impairment into dementia.

The study, published in Nature Metabolism, combined an analysis of health records of experiments involving human brain tissue and genetically modified mice. It showed that the supplement affected the brain in people already showing early signs of cognitive decline.

The findings, however, do not prove that glucosamine increases the progression of Alzheimer’s disease faster in humans.

What Is Glucosamine?

Glucosamine is a sugar-related compound widely sold as an over-the-counter supplement for joint discomfort and joint health. It is also found naturally in cartilage. It is used by older adults, the same age group in which cognitive impairment and dementia become more common.

Researchers at the University of Florida analysed health records collected between 2012 and 2024 to investigate whether glucosamine use was linked with Alzheimer's disease and related dementias.

"In the United States, there are about 7 million people living with Alzheimer's and millions more with related dementias such as Lewy body or frontotemporal dementia," said senior author Ramon Sun, Ph.D., Director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of UF's McKnight Brain Institute. "A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse."

Also read: Muscle Loss In Middle Age May Signal Dementia Risk, Study Finds

What Were The Study's Findings?

About 8% of patients in both groups were using glucosamine supplement. This included 2,750 people with mild cognitive impairment and 1,896 people who already had Alzheimer's disease or a related dementia.

After accounting for age, sex and demographic factors, researchers found that people with mild cognitive impairment who used glucosamine had a 25% higher likelihood of progressing to dementia compared with those without documented use.

Among people who already had Alzheimer's disease or a related dementia, glucosamine use was also associated with a 25% higher risk of death during the study period. However, these were findings were based on collective health records, not a controlled clinical trial.

“The electronic health record data are very provocative,” said Matt Gentry, Ph.D., a study co-author. “While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention.”

Also read: Rabies Day Exclusive: ‘We Need To Target The Source’ For A Rabies-Free India By 2030, Says Veterinary Epidemiologist

Glucosamine's Effects On Brain

The researchers identified a possible biological explanation involving a process called glycosylation. In simple terms, glycosylation involves attaching sugar structures to proteins. This is a normal process that helps proteins fold correctly, move around cells and perform their functions.

But the researchers found evidence that this process becomes excessively active in Alzheimer's disease. Their analysis suggested that glucosamine may intensify this abnormal “sugar-tagging” process in the brain.

The researchers tested the idea in genetically modified mice. Glucosamine increased the attachment of sugar molecules to proteins inside brain cells. The subjected mice's ability to recognise familiar animals also worsened.

When researchers used a chemical treatment to suppress the sugar-attachment process, the mice showed improved memory performance.

This does not prove the same mechanism occurs in humans, but it gave researchers a possible biological explanation for the association seen in the health records.

The researchers also examined brain tissue from people who had Alzheimer's disease. They found significantly more sugar attachment to proteins in Alzheimer's brain tissue compared to tissue from people without the disease. Taken together, the health-record analysis, mouse experiments and human brain-tissue findings point toward a connection between altered metabolism and Alzheimer's progression.

Despite the observation, a controlled clinical trial is needed to determine whether glucosamine itself accelerates Alzheimer's progression and whether certain patients are vulnerable.

Fighting cancer is “brutal and unrelenting,” said White House Chief of Staff Susie Wiles, who is now cancer-free after undergoing treatment for early-stage breast cancer.

In an op-ed published Sunday in USA Today, Wiles described undergoing chemotherapy while continuing to lead the White House staff for President Donald Trump.

She said some days, simply getting out of bed and going to work took all her strength. The disease, treatment, test results and uncertainty about what came next occupied her thoughts from the moment she woke up and sometimes even while she slept.

‘Even The Strongest Mind Can Be Overtaken’

“Even the strongest mind can be overtaken by it. At times, mine was,” Wiles wrote.

“Fighting for your health while remaining fully committed to your work can feel impossible,” she said, adding that determination and “perhaps some measure of mind over matter” helped her maintain that balance.

Wiles acknowledged that continuing to work during cancer treatment may not be possible or right for everyone. For her, she said, work provided “a mission larger than myself.”

“Maintaining that balance was not easy,” Wiles wrote, saying the experience gave her “profound respect and empathy” for everyone undergoing cancer treatment.

“It drains you physically, mentally, emotionally and spiritually,” she added.

Also read: From 365 Shots To 52: How Could Lilly’s Newly-Approved Weekly Insulin Injection Change Diabetes Care

Wiles said cancer can shrink a person’s world to chemotherapy appointments, blood tests, scans, medications and side effects.

“There is a temptation to measure each day by how sick you feel,” she wrote. She said she worked hard not to let breast cancer become the center of everything.

“I directed as much of my energy as I could toward doing my job,” Wiles wrote. “People depended on me to be strong and clear-eyed, and I was determined not to let them down.”

Her Team Helped Carry The Burden

Wiles said cancer affected her stamina, mobility and focus, making the support of her colleagues crucial.

“People stepped forward without hesitation, filled every gap, carried additional weight and never allowed me to feel that I was carrying this burden alone. I will never be able to repay them,” she wrote.

She also credited her family and two daughters, who “traveled every step of this road with me.”

After surgery, pathology showed no residual cancer. Wiles announced on September 16 that she was cancer-free after receiving clear pathology results at the Mayo Clinic. She had disclosed her early-stage breast cancer diagnosis in March.

She said chemotherapy tested her in ways she could never have anticipated. Her next stage, she added, will involve rebuilding what treatment took from her.

“Cancer does not have to take away who you are,” she wrote.

Wiles Thanks Trump And Her Family

Wiles thanked Trump “for the kindness and compassion” he showed while she was undergoing treatment.

Trump had publicly praised Wiles during her cancer battle, saying in a prerecorded message in May that she was winning her fight.

Wiles also credited her family, friends, colleagues and doctors for helping her through the ordeal.

In a post on X, she said she rarely writes about herself but wanted to share what it was like to fight cancer while continuing to do a job she loves.

“Cancer tried to make my world smaller. I was determined not to let it,” she wrote. She said she hoped her account could offer strength to someone still fighting the disease.

For years, people with type 2 diabetes who needed insulin had to administer an injection daily. Eli Lilly’s newly approved insulin is set to bring a dramatic reduction in that burden from roughly 365 injections a year to just 52.

The US Food and Drug Administration (FDA) has approved Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes. It is designed to provide a steady level of insulin over seven days and is used alongside diet and exercise to control blood sugar. Find out how different weekly insulin is from the daily shots that patients are used to?

Lilly's Once-Weekly Insulin Gets FDA Approval

Insulin is a hormone that helps glucose move from the bloodstream into cells, where it can be used for energy. It also helps reduce the amount of glucose produced by the liver. People with type 2 diabetes may eventually need insulin when their bodies do not produce enough of it or cannot use it effectively.

Basal insulin is long-acting insulin designed to work in the background throughout the day and night, helping keep blood sugar levels under control between meals and overnight.

Until now, commonly used basal insulins like insulin glargine and insulin degludec have generally required daily injections.

Onswik is a long-acting insulin analogue designed to remain active for an entire week. Instead of injecting a smaller amount every day, patients receive one subcutaneous injection on the same day each week. That could reduce the number of basal insulin injections by more than 300 a year compared with daily treatment.

For someone who finds daily injections difficult to maintain, that development could be gamechanging.

Also read: CagriSema Beats Lilly’s Mounjaro & Zepbound In New Trial: All About Novo’s Next-Gen Obesity Drug

Comparison Between Weekly Insulin & Daily Insulin

Lilly's late-stage QWINT programme included more than 3,400 adults with type 2 diabetes across four Phase 3 studies. Onswik met its primary goal in each study, reducing HbA1c, a measure of average blood sugar over time, by an amount that was not inferior to daily basal insulin.

The studies included people who had never previously used insulin as well as people already receiving insulin treatment.

So the significance of the approval is not that weekly insulin necessarily works better than daily insulin. Rather, it offers comparable blood-sugar control with far fewer injections.

Taking insulin every day can become another task in an already demanding diabetes care routine. Missed or delayed doses can make blood sugar management more difficult. A weekly option could simplify treatment for some patients and potentially make it easier to stay consistent. But convenience does not mean the treatment becomes risk-free.

Also read: Hundreds Of American GLP-1 Users Sue Novo Nordisk, Eli Lilly Over Vision Loss: What Is NAION?

What Are The Risks & Who Can Take It?

The most important risk remains hypoglycaemia, or dangerously low blood sugar, which is a known risk with insulin.

Severe hypoglycaemia can cause confusion, seizures, loss of consciousness and, in serious cases, death.

Other reported adverse effects of Onswik include allergic reactions, injection-site reactions, changes in fat tissue at injection sites, itching, rash, swelling and weight gain.

The FDA also warns about medication errors and accidental overdose, low potassium levels and fluid retention or heart failure when the medicine is used with certain other drugs.

The FDA approval is specifically for adults with type 2 diabetes. Onswik is not recommended for people with type 1 diabetes due to the risk of severe hypoglycaemia. It is also not a replacement for other aspects of diabetes management.